GENI vs SRAD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

GENI

69.6
AI Score
VS
GENI Wins

SRAD

56.2
AI Score

Investment Advisor Scores

GENI

70score
Recommendation
HOLD

SRAD

56score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GENI SRAD Winner
Forward P/E 51.0204 30.303 SRAD
PEG Ratio 0 0 Tie
Revenue Growth 64.7% 18.9% GENI
Earnings Growth 0.0% -39.9% GENI
Tradestie Score 69.6/100 56.2/100 GENI
Profit Margin -23.0% 1.2% SRAD
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

GENI 1M: -18.9% · 3M: -9.1% SRAD 1M: -9.0% · 3M: -27.0%

Current Technical Phase

GENI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 43

RSI (14): 42.9 · Price: $6.02

SRAD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.9%), weak momentum, RSI 40

RSI (14): 39.9 · Price: $11.76

Fundamentals Snapshot

Metric GENI SRAD
Market Cap — —
Forward P/E 5.6 30.2
Trailing P/E — 197.7
Revenue (TTM) — —
Revenue Growth 0.6% 0.2%
Gross Margin 0.3% 0.3%
Operating Margin -0.1% 0.1%
EPS -0.66 0.06
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GENI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.